1
|
Pourmadadi M, Ghaemi A, Shamsabadipour A, Rajabzadeh-Khosroshahi M, Shaghaghi M, Rahdar A, Pandey S. Nanoparticles loaded with Daunorubicin as an advanced tool for cancer therapy. Eur J Med Chem 2023; 258:115547. [PMID: 37327678 DOI: 10.1016/j.ejmech.2023.115547] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2023] [Revised: 06/03/2023] [Accepted: 06/04/2023] [Indexed: 06/18/2023]
Abstract
Nowadays, with the advent of cutting-edge technologies in the field of biotechnology, some highly advanced medical methods are introduced to treat cancers more efficiently. In the chemotherapy processes, anti-cancer drugs can be encapsulated in a stimuli-responsive coating which is capable of being functionalized by diverse ligands to increase the biocompatibility and control drug release behavior in a targeted drug delivery system. Nanoparticles (NPs) are playing an important role as nanocarriers in chemotherapy procedures, recently, numerous novel drug delivery systems have been studied which employed diverse types of NPs with remarkable structural features like porous nanocarriers with active and extended surface areas to enhance the drug loading and delivery efficacy. In this study, Daunorubicin (DAU) as an effective anti-cancer drug for treating various cancers introduced, and its application for novel drug delivery systems either as a single chemotherapy agent or co-delivery alongside other drugs with diverse NPs has been reviewed.
Collapse
Affiliation(s)
- Mehrab Pourmadadi
- Department of Biotechnology, School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran
| | - Amirhossein Ghaemi
- Department of Biotechnology, School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran
| | - Amin Shamsabadipour
- Department of Biotechnology, School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran; Department of Chemical and Petroleum Engineering, Sharif University of Technology, Tehran, Iran
| | - Maryam Rajabzadeh-Khosroshahi
- Department of Biotechnology, School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran
| | - Meysam Shaghaghi
- Department of Biotechnology, School of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran
| | - Abbas Rahdar
- Department of Physics, University ofZabol, Zabol, 98613-35856, Iran.
| | - Sadanand Pandey
- Department of Chemistry, College of Natural Science, Yeungnam University, 280 Daehak-Ro, Gyeongsan, 38541, South Korea.
| |
Collapse
|
2
|
Jalili F, Zarei M, Zolfigol MA, Khazaei A. Application of novel metal-organic framework [Zr-UiO-66-PDC-SO 3H]FeCl 4 in the synthesis of dihydrobenzo[ g]pyrimido[4,5- b]quinoline derivatives. RSC Adv 2022; 12:9058-9068. [PMID: 35424891 PMCID: PMC8985156 DOI: 10.1039/d1ra08710j] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Accepted: 03/08/2022] [Indexed: 01/21/2023] Open
Abstract
In the current paper, we produce a new metal-organic framework (MOF) based on Zr metal, [Zr-UiO-66-PDC-SO3H]FeCl4, via an anion exchange method, which is fully characterized by FT-IR, SEM with elemental mapping and EDX, FE-SEM and TEM. Furthermore, the use of [Zr-UiO-66-PDC-SO3H]FeCl4 as a porous catalyst was examined for the one-pot synthesis of novel dihydrobenzo[g]pyrimido[4,5-b]quinoline derivatives by reaction of 6-amino-1,3-dimethylpyrimidine-2,4(1H,3H)-dione, 2-hydroxynaphthalene-1,4-dione and various aldehydes at 100 °C with good to excellent yields.
Collapse
Affiliation(s)
- Fatemeh Jalili
- Department of Organic Chemistry, Faculty of Chemistry, Bu-Ali-Sina University 6517838965 Hamedan Iran
| | - Mahmoud Zarei
- Department of Organic Chemistry, Faculty of Chemistry, Bu-Ali-Sina University 6517838965 Hamedan Iran
| | - Mohammad Ali Zolfigol
- Department of Organic Chemistry, Faculty of Chemistry, Bu-Ali-Sina University 6517838965 Hamedan Iran
| | - Ardeshir Khazaei
- Department of Organic Chemistry, Faculty of Chemistry, Bu-Ali-Sina University 6517838965 Hamedan Iran
| |
Collapse
|
3
|
Ibrahim M, Abuwatfa WH, Awad NS, Sabouni R, Husseini GA. Encapsulation, Release, and Cytotoxicity of Doxorubicin Loaded in Liposomes, Micelles, and Metal-Organic Frameworks: A Review. Pharmaceutics 2022; 14:pharmaceutics14020254. [PMID: 35213987 PMCID: PMC8875190 DOI: 10.3390/pharmaceutics14020254] [Citation(s) in RCA: 34] [Impact Index Per Article: 17.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2021] [Revised: 01/14/2022] [Accepted: 01/16/2022] [Indexed: 12/31/2022] Open
Abstract
Doxorubicin (DOX) is one of the most widely used anthracycline anticancer drugs due to its high efficacy and evident antitumoral activity on several cancer types. However, its effective utilization is hindered by the adverse side effects associated with its administration, the detriment to the patients’ quality of life, and general toxicity to healthy fast-dividing cells. Thus, delivering DOX to the tumor site encapsulated inside nanocarrier-based systems is an area of research that has garnered colossal interest in targeted medicine. Nanoparticles can be used as vehicles for the localized delivery and release of DOX, decreasing the effects on neighboring healthy cells and providing more control over the drug’s release and distribution. This review presents an overview of DOX-based nanocarrier delivery systems, covering loading methods, release rate, and the cytotoxicity of liposomal, micellar, and metal organic frameworks (MOFs) platforms.
Collapse
Affiliation(s)
- Mihad Ibrahim
- Department of Chemical Engineering, College of Engineering, American University of Sharjah, Sharjah P.O. Box 26666, United Arab Emirates; (M.I.); (W.H.A.); (N.S.A.); (R.S.)
| | - Waad H. Abuwatfa
- Department of Chemical Engineering, College of Engineering, American University of Sharjah, Sharjah P.O. Box 26666, United Arab Emirates; (M.I.); (W.H.A.); (N.S.A.); (R.S.)
- Materials Science and Engineering Program, College of Arts and Sciences, American University of Sharjah, Sharjah P.O. Box 26666, United Arab Emirates
| | - Nahid S. Awad
- Department of Chemical Engineering, College of Engineering, American University of Sharjah, Sharjah P.O. Box 26666, United Arab Emirates; (M.I.); (W.H.A.); (N.S.A.); (R.S.)
| | - Rana Sabouni
- Department of Chemical Engineering, College of Engineering, American University of Sharjah, Sharjah P.O. Box 26666, United Arab Emirates; (M.I.); (W.H.A.); (N.S.A.); (R.S.)
- Materials Science and Engineering Program, College of Arts and Sciences, American University of Sharjah, Sharjah P.O. Box 26666, United Arab Emirates
| | - Ghaleb A. Husseini
- Department of Chemical Engineering, College of Engineering, American University of Sharjah, Sharjah P.O. Box 26666, United Arab Emirates; (M.I.); (W.H.A.); (N.S.A.); (R.S.)
- Materials Science and Engineering Program, College of Arts and Sciences, American University of Sharjah, Sharjah P.O. Box 26666, United Arab Emirates
- Correspondence: ; Tel.: +971-6-515-2970
| |
Collapse
|
4
|
Chen X, Hu L, Wang Y, Sun W, Yang C. Single Cell Gene Co-Expression Network Reveals FECH/CROT Signature as a Prognostic Marker. Cells 2019; 8:cells8070698. [PMID: 31295943 PMCID: PMC6678878 DOI: 10.3390/cells8070698] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2019] [Revised: 07/03/2019] [Accepted: 07/08/2019] [Indexed: 02/06/2023] Open
Abstract
Aberrant activation of signaling pathways is frequently observed and reported to be associated with the progression and poor prognosis of prostate cancer (PCa). We aimed to identify key biological processes regulated by androgen receptor (AR) using gene co-expression network from single cell resolution. The bimodal index was used to evaluate whether two subpopulations exist among the single cells. Gene expression among single cells revealed averaging pitfalls and bimodality pattern. Weighted gene co-expression network analysis (WGCNA) was used to identify modules of highly correlated genes. Twenty-nine gene modules were identified and AR-regulated modules were screened by significantly overlapping reported androgen induced differentially expressed genes. The biological function "generation of precursor metabolites and energy" was significantly enriched by AR-regulated modules with bimodality, presenting differential androgen response among subpopulations. Integrating with public ChIP-seq data, two genes FECH, and CROT has AR binding sites. Public in vitro studies also show that androgen regulates FECH and CROT. After receiving androgen deprivation therapy, patients lowly express FECH and CROT. Further survival analysis indicates that FECH/CROT signature can predict PCa recurrence. We reveal the heterogeneous function of "generation of precursor metabolites and energy" upon androgen stimulation from the perspective of single cells. Inhibitors targeting this biological process will facilitate to prevent prostate cancer progression.
Collapse
Affiliation(s)
- Xin Chen
- Guangdong Key Laboratory of IoT Information Technology, School of Automation, Guangdong University of Technology, Guangzhou 510006, China
| | - Lingling Hu
- Faculty of Health Sciences, University of Macau, Macau 999078, China
| | - Yuan Wang
- Faculty of Health Sciences, University of Macau, Macau 999078, China
| | - Weijun Sun
- Guangdong Key Laboratory of IoT Information Technology, School of Automation, Guangdong University of Technology, Guangzhou 510006, China
| | - Chao Yang
- Guangdong Key Laboratory of IoT Information Technology, School of Automation, Guangdong University of Technology, Guangzhou 510006, China.
| |
Collapse
|
5
|
Severi L, Losi L, Fonda S, Taddia L, Gozzi G, Marverti G, Magni F, Chinello C, Stella M, Sheouli J, Braicu EI, Genovese F, Lauriola A, Marraccini C, Gualandi A, D'Arca D, Ferrari S, Costi MP. Proteomic and Bioinformatic Studies for the Characterization of Response to Pemetrexed in Platinum Drug Resistant Ovarian Cancer. Front Pharmacol 2018; 9:454. [PMID: 29867465 PMCID: PMC5952181 DOI: 10.3389/fphar.2018.00454] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2018] [Accepted: 04/18/2018] [Indexed: 12/12/2022] Open
Abstract
Proteomics and bioinformatics are a useful combined technology for the characterization of protein expression level and modulation associated with the response to a drug and with its mechanism of action. The folate pathway represents an important target in the anticancer drugs therapy. In the present study, a discovery proteomics approach was applied to tissue samples collected from ovarian cancer patients who relapsed after the first-line carboplatin-based chemotherapy and were treated with pemetrexed (PMX), a known folate pathway targeting drug. The aim of the work is to identify the proteomic profile that can be associated to the response to the PMX treatment in pre-treatement tissue. Statistical metrics of the experimental Mass Spectrometry (MS) data were combined with a knowledge-based approach that included bioinformatics and a literature review through ProteinQuest™ tool, to design a protein set of reference (PSR). The PSR provides feedback for the consistency of MS proteomic data because it includes known validated proteins. A panel of 24 proteins with levels that were significantly different in pre-treatment samples of patients who responded to the therapy vs. the non-responder ones, was identified. The differences of the identified proteins were explained for the patients with different outcomes and the known PMX targets were further validated. The protein panel herein identified is ready for further validation in retrospective clinical trials using a targeted proteomic approach. This study may have a general relevant impact on biomarker application for cancer patients therapy selection.
Collapse
Affiliation(s)
- Leda Severi
- Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
| | - Lorena Losi
- Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
| | - Sergio Fonda
- Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
| | - Laura Taddia
- Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
| | - Gaia Gozzi
- Department of Biomedical Science, Metabolic Science and Neuroscience, University of Modena and Reggio Emilia, Modena, Italy
| | - Gaetano Marverti
- Department of Biomedical Science, Metabolic Science and Neuroscience, University of Modena and Reggio Emilia, Modena, Italy
| | - Fulvio Magni
- Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy
| | - Clizia Chinello
- Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy
| | - Martina Stella
- Department of Medicine and Surgery, University of Milano Bicocca, Monza, Italy
| | - Jalid Sheouli
- Department of Gynecology, European Competence Center for Ovarian Cancer, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Elena I Braicu
- Department of Gynecology, European Competence Center for Ovarian Cancer, Charité-Universitätsmedizin Berlin, Berlin, Germany
| | - Filippo Genovese
- Centro Interdipartimentale Grandi Strumenti, University of Modena and Reggio Emilia, Modena, Italy
| | - Angela Lauriola
- Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
| | - Chiara Marraccini
- Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
| | - Alessandra Gualandi
- Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
| | - Domenico D'Arca
- Department of Biomedical Science, Metabolic Science and Neuroscience, University of Modena and Reggio Emilia, Modena, Italy
| | - Stefania Ferrari
- Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
| | - Maria P Costi
- Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy
| |
Collapse
|
6
|
Baron BW, Baron RM, Baron JM. Reticulocytes Are an Enriched Source of the RUVBL1 Protein. Acta Haematol 2017; 138:162-165. [PMID: 28982102 DOI: 10.1159/000480449] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2017] [Accepted: 08/19/2017] [Indexed: 11/19/2022]
Affiliation(s)
- Beverly W Baron
- Department of Pathology, The University of Chicago, Chicago, IL, USA
| | | | | |
Collapse
|
7
|
Ozdian T, Holub D, Maceckova Z, Varanasi L, Rylova G, Rehulka J, Vaclavkova J, Slavik H, Moudry P, Znojek P, Stankova J, de Sanctis JB, Hajduch M, Dzubak P. Proteomic profiling reveals DNA damage, nucleolar and ribosomal stress are the main responses to oxaliplatin treatment in cancer cells. J Proteomics 2017; 162:73-85. [DOI: 10.1016/j.jprot.2017.05.005] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2016] [Revised: 04/26/2017] [Accepted: 05/02/2017] [Indexed: 12/18/2022]
|
8
|
Estrogen Enhances the Expression of the Multidrug Transporter Gene ABCG2-Increasing Drug Resistance of Breast Cancer Cells through Estrogen Receptors. Int J Mol Sci 2017; 18:ijms18010163. [PMID: 28098816 PMCID: PMC5297796 DOI: 10.3390/ijms18010163] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2016] [Revised: 01/06/2017] [Accepted: 01/06/2017] [Indexed: 12/16/2022] Open
Abstract
Background: Multidrug resistance is a major obstacle in the successful therapy of breast cancer. Studies have proved that this kind of drug resistance happens in both human cancers and cultured cancer cell lines. Understanding the molecular mechanisms of drug resistance is important for the reasonable design and use of new treatment strategies to effectively confront cancers. Results: In our study, ATP-binding cassette sub-family G member 2 (ABCG2), adenosine triphosphate (ATP) synthase and cytochrome c oxidase subunit VIc (COX6C) were over-expressed more in the MCF-7/MX cell line than in the normal MCF7 cell line. Therefore, we believe that these three genes increase the tolerance of MCF7 to mitoxantrone (MX). The data showed that the high expression of COX6C made MCF-7/MX have more stable on mitochondrial membrane potential (MMP) and reactive oxygen species (ROS) expression than normal MCF7 cells under hypoxic conditions. The accumulation of MX was greater in the ATP-depleted treatment MCF7/MX cells than in normal MCF7/MX cells. Furthermore, E2 increased the tolerance of MCF7 cells to MX through inducing the expression of ABCG2. However, E2 could not increase the expression of ABCG2 after the inhibition of estrogen receptor α (ERα) in MCF7 cells. According to the above data, under the E2 treatment, MDA-MB231, which lacks ER, had a higher sensitivity to MX than MCF7 cells. Conclusions: E2 induced the expression of ABCG2 through ERα and the over-expressed ABCG2 made MCF7 more tolerant to MX. Moreover, the over-expressed ATP synthase and COX6c affected mitochondrial genes and function causing the over-expressed ABCG2 cells pumped out MX in a concentration gradient from the cell matrix. Finally lead to chemoresistance.
Collapse
|
9
|
Wang Q, Wang YL, Wang K, Yang JL, Cao CY. Polyamine analog TBP inhibits proliferation of human K562 chronic myelogenous leukemia cells by induced apoptosis. Oncol Lett 2014; 9:278-282. [PMID: 25435975 PMCID: PMC4246664 DOI: 10.3892/ol.2014.2615] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2014] [Accepted: 09/22/2014] [Indexed: 12/23/2022] Open
Abstract
The aim of the present study was to investigate the effects of the novel polyamine analog tetrabutyl propanediamine (TBP) on the growth of K562 chronic myelogenous leukemia (CML) cells and the underlying mechanism of these effects. MTT was used for the analysis of cell proliferation and flow cytometry was performed to analyze cell cycle distribution. DNA fragmentation analysis and Annexin V/propidium iodide double staining were used to identify apoptotic cells. The activity of the key enzymes in polyamine catabolism was detected using chemiluminescence. TBP can induce apoptosis and significantly inhibit K562 cell proliferation in a time- and dose-dependent manner. TBP treatment significantly induced the enzyme activity of spermine oxidase and acetylpolyamine oxidase in K562 cells, and also enhanced the inhibitory effect of the antitumor drug doxorubicin on K562 cell proliferation. As a novel polyamine analog, TBP significantly inhibited proliferation and induced apoptosis in K562 cells by upregulating the activity of the key enzymes in the polyamine catabolic pathways. TBP also increased the sensitivity of the K562 cells to the antitumor drug doxorubicin. These data indicate an important potential value of TBP for clinical therapy of human CML.
Collapse
Affiliation(s)
- Qing Wang
- Institute of Molecular Biology, Medical College, China Three Gorges University, Yichang, Hubei 443002, P.R. China
| | - Yan-Lin Wang
- Institute of Molecular Biology, Medical College, China Three Gorges University, Yichang, Hubei 443002, P.R. China
| | - Kai Wang
- College of Chemical and Pharmacy, Wuhan Engineering University, Wuhan, Hubei 430073, P.R. China
| | - Jian-Lin Yang
- Institute of Molecular Biology, Medical College, China Three Gorges University, Yichang, Hubei 443002, P.R. China
| | - Chun-Yu Cao
- Institute of Molecular Biology, Medical College, China Three Gorges University, Yichang, Hubei 443002, P.R. China
| |
Collapse
|
10
|
Wright EP, Padula MP, Higgins VJ, Aldrich-Wright JR, Coorssen JR. A Systems Biology Approach to Understanding the Mechanisms of Action of an Alternative Anticancer Compound in Comparison to Cisplatin. Proteomes 2014; 2:501-526. [PMID: 28250393 PMCID: PMC5302693 DOI: 10.3390/proteomes2040501] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2014] [Revised: 09/19/2014] [Accepted: 10/29/2014] [Indexed: 01/22/2023] Open
Abstract
Many clinically available anticancer compounds are designed to target DNA. This commonality of action often yields overlapping cellular response mechanisms and can thus detract from drug efficacy. New compounds are required to overcome resistance mechanisms that effectively neutralise compounds like cisplatin and those with similar chemical structures. Studies have shown that 56MESS is a novel compound which, unlike cisplatin, does not covalently bind to DNA, but is more toxic to many cell lines and active against cisplatin-resistant cells. Furthermore, a transcriptional study of 56MESS in yeast has implicated iron and copper metabolism as well as the general yeast stress response following challenge with 56MESS. Beyond this, the cytotoxicity of 56MESS remains largely uncharacterised. Here, yeast was used as a model system to facilitate a systems-level comparison between 56MESS and cisplatin. Preliminary experiments indicated that higher concentrations than seen in similar studies be used. Although a DNA interaction with 56MESS had been theorized, this work indicated that an effect on protein synthesis/ degradation was also implicated in the mechanism(s) of action of this novel anticancer compound. In contrast to cisplatin, the different mechanisms of action that are indicated for 56MESS suggest that this compound could overcome cisplatin resistance either as a stand-alone treatment or a synergistic component of therapeutics.
Collapse
Affiliation(s)
- Elise P Wright
- Molecular Physiology Department, and the Molecular Medicine Research Group, School of Medicine, University of Western Sydney, Campbelltown, NSW 2751, Australia.
| | - Matthew P Padula
- Proteomics Core Facility, Faculty of Science, University of Technology, Sydney, NSW 2007, Australia.
| | - Vincent J Higgins
- School of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington, NSW 2052, Australia.
| | - Janice R Aldrich-Wright
- Molecular Physiology Department, and the Molecular Medicine Research Group, School of Medicine, University of Western Sydney, Campbelltown, NSW 2751, Australia.
- School of Science and Health, University of Western Sydney, Campbelltown, NSW 2751, Australia.
| | - Jens R Coorssen
- Molecular Physiology Department, and the Molecular Medicine Research Group, School of Medicine, University of Western Sydney, Campbelltown, NSW 2751, Australia.
| |
Collapse
|